Literature DB >> 26910177

Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy.

Maria Carmela Pera, Giovanna Randazzo, Silvia Masnada, Serena Donetti Dontin, Valentina De Giorgis, Umberto Balottin, Pierangelo Veggiotti.   

Abstract

The aim of this retrospective study of children affected by epileptic encephalopathy was to evaluate seizure frequency, electroencephalographic pattern and neuropsychological status, before and after intravenous methylprednisolone therapy. Eleven children with epileptic encephalopathy were administered one cycle of intravenous methylprednisolone (15-30 mg/kg/day for three consecutive days, once a month for four months) in addition to constant dosages of their regular antiepileptic drugs. The treatment resulted in statistically significant reductions of generalized slow spike-and-wave discharges (p<0.0028) and seizure frequency (p<0.013), which persisted even after methylprednisolone pulse therapy was stopped. A globally positive outcome was noted in 9/11 patients (81.8%). This methylprednisolone treatment regimen did not cause significant or persistent adverse effects. We suggest that children with epileptic encephalopathy without an underlying structural lesion could be the best candidates for intravenous methylprednisolone pulse therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26910177      PMCID: PMC4610752          DOI: 10.11138/fneur/2015.30.3.173

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  28 in total

1.  Intravenous methylprednisolone pulse therapy in a young girl with intractable absence seizures.

Authors:  Rela Lichtenfeld; Eli Heyman; Revital Gandelman-Marton; Amir Livne; Eli Lahat
Journal:  Isr Med Assoc J       Date:  2010-03       Impact factor: 0.892

2.  Treatment of epilepsy with electrical status epilepticus during slow sleep and its related disorders.

Authors:  Miki Inutsuka; Katsuhiro Kobayashi; Makio Oka; Junri Hattori; Yoko Ohtsuka
Journal:  Brain Dev       Date:  2006-01-10       Impact factor: 1.961

3.  Methylprednisolone for the treatment of children with refractory epilepsy.

Authors:  R A Sevilla-Castillo; G C Palacios; J Ramirez-Campos; M Mora-Puga; R Diaz-Bustos
Journal:  Neuropediatrics       Date:  2010-05-05       Impact factor: 1.947

4.  Effects of high-dose intravenous corticosteroid therapy in Landau-Kleffner syndrome.

Authors:  T Tsuru; M Mori; M Mizuguchi; M Y Momoi
Journal:  Pediatr Neurol       Date:  2000-02       Impact factor: 3.372

Review 5.  Corticosteroids in the management of the paediatric epilepsies.

Authors:  R Gupta; R Appleton
Journal:  Arch Dis Child       Date:  2005-04       Impact factor: 3.791

6.  Efficacy of very high dose steroid treatment in a case of Landau-Kleffner syndrome.

Authors:  Siobhan Gallagher; Shelley Weiss; Janis Oram Cardy; Tom Humphries; Karen E Harman; Shay Menascu
Journal:  Dev Med Child Neurol       Date:  2006-09       Impact factor: 5.449

Review 7.  The epileptic encephalopathies of infancy and childhood.

Authors:  Elaine Wirrell; Kevin Farrell; Sharon Whiting
Journal:  Can J Neurol Sci       Date:  2005-11       Impact factor: 2.104

Review 8.  Immuno- and antiinflammatory therapies in epileptic disorders.

Authors:  Çiğdem Özkara; Federico Vigevano
Journal:  Epilepsia       Date:  2011-05       Impact factor: 5.864

9.  Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy.

Authors:  S J You; D E Jung; H D Kim; H S Lee; H-C Kang
Journal:  Eur J Paediatr Neurol       Date:  2007-10-22       Impact factor: 3.140

Review 10.  Epilepsy in children.

Authors:  Renzo Guerrini
Journal:  Lancet       Date:  2006-02-11       Impact factor: 79.321

View more
  4 in total

Review 1.  Lennox-Gastaut syndrome: a comprehensive review.

Authors:  Ali A Asadi-Pooya
Journal:  Neurol Sci       Date:  2017-11-09       Impact factor: 3.307

Review 2.  Neurovascular glucocorticoid receptors and glucocorticoids: implications in health, neurological disorders and drug therapy.

Authors:  Sherice Williams; Chaitali Ghosh
Journal:  Drug Discov Today       Date:  2019-09-18       Impact factor: 7.851

3.  Non-convulsive status epilepticus in two patients with tuberous sclerosis.

Authors:  Yuksel Erdal; Alper Alnak; Ozgur Oztop; Pınar Tekturk; Zuhal Yapici
Journal:  Childs Nerv Syst       Date:  2019-10-29       Impact factor: 1.475

4.  Risk factors associated with the development of seizures among adult patients treated with ertapenem: A matched case-control study.

Authors:  Yi-Chien Lee; Yun-Jhong Huang; Miao-Chiu Hung; Sheng-Che Hung; Chih-Yen Hsiao; Hui-Ling Cho; Li-Fen Lai; Show-Hwa Tong; Jann-Tay Wang
Journal:  PLoS One       Date:  2017-07-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.